Title (100/150): UBTF Tandem Duplications in Pediatric MDS and AML: Implications for Clinical Screening and Diagnosis

Short Title (46/50): UBTF-TDs in Pediatric MDS and AML

Authors and Affiliations:
Juan M. Barajas¹,+, Masayuki Umeda¹,+, Lisett Contreras¹, Mahsa Khanlari¹, Tamara Westover¹, Michael P. Walsh¹, Emily Xiong¹, Chenchen Yang², Brittney Otero², Marc Arribas-Layton², Sherif Abdelhamed¹, Guangchun Song¹, Xiaotu Ma³, Melvin E. Thomas 3rd¹, Jing Ma¹, Jeffery M. Klco¹,*

+ Equal first authors

* Corresponding author

1. Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
2. Mission Bio, South San Francisco, CA
3. Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Contact Information/Corresponding authors:
*Correspondence: jeffery.klco@stjude.org

Jeffery M. Klco: Mail Stop 342, Room D4047B, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, Phone: (901) 595-6807, Fax: (901) 595-5947, Email: jeffery.klco@stjude.org

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
**Key Points:**

- Largest cohort of pediatric UBTF-TD in myeloid neoplasms reported to date.
- Use of single-cell DNA+protein sequencing technology in 3 UBTF-TD samples reveals a clonal evaluation pattern characterized by sequential acquisition of WT1 and FLT3 mutations and a more stem cell-like protein expression pattern.
- Pediatric MDS and AML patients with UBTF-TD alterations dysplastic features with an increase erythroid precursors.
- Tandem duplications in exon 9 of UBTF represent a rare but functionally equivalent subgroup of UBTF-TD myeloid neoplasms.

**Impact Statement:**

UBTF tandem duplications (TD) are subtype-defining genomic alterations in adult and pediatric myeloid neoplasms. Here, we provide a comprehensive characterization of the largest cohort of pediatric UBTF-TD cases to date, including the recognition of additional UBTF alterations that mimic the exon 13 duplications in pediatric AML.
Abstract, (200/200 words):

Recent genomic studies in adult and pediatric acute myeloid leukemia (AML) demonstrated recurrent in-frame tandem duplications (TD) in exon 13 of upstream binding transcription factor (UBTF). These alterations, which account for ~4.3% of AMLs in childhood and up to 3% in adult AMLs under 60, are subtype-defining and associated with poor outcomes. Here, we provide a comprehensive investigation into the clinicopathological features of UBTF-TD myeloid neoplasms in childhood, including 89 unique pediatric AML and 6 myelodysplastic syndrome (MDS) cases harboring a tandem duplication in exon 13 of UBTF. We demonstrate that UBTF-TD myeloid tumors are associated with dysplastic features, low bone marrow blast infiltration, and low white blood cell count. Furthermore, using bulk and single-cell analyses, we confirm that UBTF-TD is an early and clonal event associated with a distinct transcriptional profile, whereas the acquisition of FLT3 or WT1 mutations is associated with more stem cell-like programs. Lastly, we report rare duplications within exon 9 of UBTF that phenocopy exon 13 duplications, expanding the spectrum of UBTF alterations in pediatric myeloid tumors. Collectively, we comprehensively characterize pediatric AML and MDS with UBTF-TD and highlight key clinical and pathologic features that distinguish this new entity from other molecular subtypes of AML.

Key Words:

UBTF Tandem Duplications; Pediatric and Adult Acute Myeloid Leukemia; Myeloid Neoplasms
Pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are characterized by unique genetic backgrounds when compared to those in adults (1-3). Recurrent tandem duplications (TD) of exon 13 of upstream binding transcription factor (UBTF) were only recently identified as potential initiating events in pediatric AML (4-7), accounting for about 4% of newly diagnosed pediatric AML. PCR-based screening covering exon 13 of UBTF also identified UBTF-TD alterations in large adult AML cohorts (8, 9). These studies significantly contributed to the accumulation of evidence of UBTF-TD alterations in adult AML. However, PCR-based methods potentially underestimate partial tandem duplications (PTD) extending outside the regions covered by amplicons or possible alterations not involving exon 13 (9). Also, data on UBTF alterations in pediatric AML is limited to screening of relatively small cohorts (4, 5), and further efforts are needed to accumulate more knowledge about the biology and clinicopathologic features of this disease entity.

UBTF encodes the UBTF/UBF protein known to regulate ribosomal RNA (rRNA) transcription and nucleolar formation (10, 11). We previously reported that expression of exon 13 UBTF-TD in cord blood CD34+ (cbCD34+) cells is sufficient to induce cellular proliferation, increase clonogenic activity and the establishment of a transcriptional signature that recapitulates that observed in UBTF-TD AML patient samples (4). Our previous analyses also demonstrated that UBTF-TD do not occur with other canonical alterations in pediatric AML, but that UBTF-TD AMLs often harbor additional somatic mutations, such as internal tandem duplications in FLT3 (FLT3-ITD) and frameshift
mutations in WT1. The acquisition of these cooperating mutations can likely contribute to the stepwise progression of the disease and clonal evolution. However, our understanding of how these cooperating mutations contribute to the cellular and disease status remains to be elucidated.

To bridge these knowledge gaps, we present an extended pediatric cohort of 89 AML and 6 MDS samples with exon 13 UBTF-TD, showing that UBTF-TD is strongly associated with dysplastic features while acquisition of FLT3-ITD is associated with progression from MDS to AML. By leveraging bulk RNA-sequencing and single cell genomics, we show that the co-occurrence of FLT3-ITD and WT1 mutations is associated with stem cell-like phenotypes. Furthermore, we identified tandem duplications within exon 9 of UBTF in two cases transcriptionally resembling exon 13 UBTF-TD AML. Exon 9 UBTF-TDs contain hydrophobic leucine-rich sequences and can induce leukemic phenotypes in cbCD34+ cells, which recapitulate findings in exon 13 UBTF-TD, suggesting that they likely have a shared mechanism and should be classified as the same molecular entity. These findings offer valuable insights to inform future diagnostic strategies and understanding of the molecular basis of UBTF-TD myeloid neoplasms.

Materials/Subjects and Methods:

Cell Culture and Analysis of cord-blood CD34+ Cell Models

UBTF-TD cbCD34+ models were generated as previously described (4). Freshly isolated cord blood CD34+ (cbCD34+) cells were transduced with lentiviral particles
from MND-PGK-mCherry constructs expressing N-terminus HA-tagged UBTF-wild-type (WT), N-terminus HA-tagged UBTF-TD, N-Terminus HA-tagged UBTF-TD78-exon9 or N-Terminus HA-tagged UBTF-TD153-exon9. Transduced cells were sorted for mCherry positivity and expanded as previously described(4). Molecular experiments were performed at 40-60 days after sorting unless otherwise noted. For cytospins, 100,000 cells were washed with 1X PBS and spun onto Superfrost Plus Microscope slides (12-660-16, Fisher Scientific) at 800 rpm for 5 min.

DNA Single-Cell Sequencing and Analysis

Single-cell targeted sequencing was performed using Tapestri System from Mission Bio (missionbio.com). A panel of 162 PCR amplicons with an average size of 260bp was designed using Tapestri Designer from Mission Bio (designer.missionbio.com), as well as a manually designed amplicon targeting the UBTF exon13 TD region. This panel consists of amplicons targeting UBTF tandem duplicated regions, common mutations in UBTF-TD AML, and mutations specific to cases presented in this manuscript (Supplemental Table 2). Cryopreserved UBTF-TD primary AML samples were thawed and subjected to dead cell removal using the EasySep™ Dead Cell Removal Kit (STEMCELL Technologies, cat# 17899). Live cells were then subjected to the Mission Bio DNA+Protein protocol per manufacturer’s instructions (missionbio.com). Libraries were then sequenced on the Novaseq platform (100M read pairs for DNA libraries and 225M read pairs for protein libraries). Bam files, loom files, h5 files, and QC metrics were produced via a customization of the Tapestri pipeline developed by Mission Bio (support.missionbio.com/hc/en-us). Analysis of the samples was completed using the
Mosaic package v3.0.1 (missionbio.github.io/mosaic/). Reads for the UBTF and FLT3-ITD calls were isolated from bam files using the pysam python package v0.21.0 (github.com/pysam-developers/pysam). Reads were then realigned to ITD contigs reported in previous studies (4) using the BWA aligner v0.7.15-r1140 (12, 13). When necessary, mutation VAFs were adjusted using pysam.

RNA-sequencing and genomic profiling

As we previously performed (1), RNA reads from newly sequenced samples and from publications were mapped to the GRCh37/hg19 human genome assembly using the StrongARM pipeline (14). Chimeric fusion detection was carried out using CICERO (v0.3.0)(15). For somatic mutations calling from RNA-seq BAM files, we applied Bambino (v1.07)(16) for SNV and RNAindel (v3.0.4) (17, 18) focusing on 87 predefined genes recurrently mutated in pediatric AML and myelodysplastic syndrome. UBTF-TD screening was performed as we have reported (4). For the cases with TWIST capture sequencing, we called mutations as previously described (4). We also collected mutation calls with DNA data from referenced publication in Supplemental Table 5.

Transcriptome analysis

Gene expression analysis was performed as previously described (1). Briefly, an RNA-seq cohort was established by integrating UBTF cases with RNA-seq data in this study (n=96) and AML in other categories from the published study (1) (n=837) and cbCD34+ cells (n=5). Reads from aligned RNA-Seq BAM files were assigned to genes and counted using HTSeq (v0.11.2) (19) with the GENCODE human release 19 gene
The count data were transformed to log2-counts per million (log2CPM) using Voom available from R package Limma (v3.50.3) (20). The top variable genes were selected using the "vst" method in Seurat package (21). The expression data were then scaled, and PCA (Principal Component Analysis) was performed on the scaled data using the top 265 variable genes. Dimension reduction was performed using UMAP (Uniform Manifold Approximation and Projection) (22) with the top 100 principal components. Differential gene expression analysis was performed by Limma between groups as indicated in each figure, and we set Log2 CPM = -1 if it is < -1 based on the Log2 CPM data distribution. \( P \) values were adjusted by the Benjamini-Hochberg method to calculate the false discovery rate (FDR) using R function p.adjust. Genes with absolute fold change > 2 and FDR < 0.05 were regarded as significantly differentially expressed. Gene Set Enrichment Analysis (GSEA) was performed by GSEA (v4.2.3) using MSigDB gene sets c2.all (v7.5.1) (23). Permutations were done 1000 times among gene sets with sizes between 15 and 1500 genes.

Statistics

Details about statistical comparisons are provided in each figure legend. All the computations were done using R or GraphPad Prism, and all \( P \) values are 2-sided.

Results:

UBTF-TD in pediatric myeloid neoplasms.

Our previous study described the molecular features of 27 pediatric AML cases with tandem duplications in exon 13 of UBTF (UBFT-TD) (4). To expand the cohort and better understand the biology, we screened RNA-sequencing data of pediatric MDS and
AML cases and identified an additional 68 cases from available datasets and previously published studies (2, 24) and routine clinical service at St. Jude Children's Research Hospital. All 95 cases (median age = 14 yrs., range = 2.4-27.4) possessed exon 13 UBTF-TDs encoding a consensus hydrophobic leucine-rich ELTRLLARM motif within the duplications (Figure 1A, Supplemental Table 1). The duplications resulted in an increased size of exon 13 (median size = 60 bp, range = 45-339) (Figure 1B).

Consistent with previous findings, UBTF-TD did not co-occur with other subtype-defining alterations and showed high variant allele frequencies (VAFs, median = 36.3%, Interquartile range (IQR) = 10.2%), further supporting our previous assertion that UBTF-TD alterations are early clonal events (1, 4) (Figure 1C). We further investigated the mutational background of this UBTF-TD cohort, confirming a strong association with a normal or trisomy 8 karyotype (Figure 1C-E), as well as with internal tandem duplications (ITD) in FLT3 (n=55, 57.9%) and mutations in WT1 (n=39, 41.1%), which are highly co-occurring (Figure 1F, \( P=0.011 \), Fisher's exact test) with 30.1% (n=29) cases harboring both alterations. In addition, 26.6% (n=25) of cases also had at least one mutation in Ras-MAPK pathway genes: NRAS (n=17, 17.9%); PTPN11 (n=5, 5.3%); RIT1 (n=5, 5.3%); NF1 (n=4, 4.2%); CBL (n=2, 2.1%); and KRAS (n=2, 2.1%). Other recurrent mutations in myeloid malignancies were rarely observed, including IDH1/IDH2 (n=3, 3.2%), BCOR (n=2, 2.1%), and RUNX1 (n=1, 1.1%). Although our previous studies only evaluated AML samples, we also identified UBTF-TD in 6 cases of MDS with normal karyotype. These include 3 out of 46 primary MDS cases (6.2%) from our previously published cohort (2). Five of the six MDS cases were classified as childhood MDS with increased blasts according to the current WHO classification (25) and lacked
known germline predispositions to pediatric MDS or monosomy 7/del7q. No FLT3-ITD mutations were detected in the 6 MDS cases, while WT1 mutations were present in 3 out of the 6 MDS cases, suggesting clonal evolutionary patterns initiating with UBTF-TD alterations.

To address clonal evolution in UBTF-TD myeloid neoplasms, we utilized a droplet-based single cell multi-omics platform from MissionBio (Figure 2)(26). This platform enables the concurrent detection of UBTF-TD alterations and somatic mutations present by a custom targeted DNA panel and cell classification by using DNA-oligo conjugated antibodies targeting cell surface markers at the single cell level (Supplemental Table 2). In a single timepoint AML case, we found a clonal UBTF-TD alteration in the myeloid population and subclonal mutations in NRAS (p.G12D), FLT3 (p.V592D), and WT1 (p.359fs), suggesting UBTF-TD as an initiating event (Supplemental Table 3, Figure 2A-B). A WT1 mutation was broadly present in the myeloid population, while NRAS or FLT3 mutations were subclonal to WT1 in a mutually exclusive manner, representing branched evolution of the UBTF-TD-WT1+ clone. We also found that cells with WT1*FLT3* mutations were associated with high stem cell marker expression (CD34, CD117, or CD123) compared with the UBTF-TD-only population, whereas the WT1*NRAS* population was characterized by low expression of these markers. In a diagnosis and relapse-paired case, we found that the identical UBTF-TD was retained through disease progression along with a FLT3-ITD alteration (Figure 2C-D). Interestingly, a minor WT1* (p.R375fs) subclone at diagnosis was eradicated after chemotherapy, whereas a different WT1* (p.R353fs) clone became dominant at relapse,
showing high expression of CD34, CD117, and CD123. These data collectively confirm that UBTF-TD is an early initiating event, while somatic mutations are subclonal to UBTF-TD, possibly contributing to disease progress toward subclones with unique expression profiles.

Clinical features of UBTF-TD pediatric myeloid neoplasms

UBTF-TD AML showed a variety of morphologic features associated with cellular differentiation, as evidenced by variable FAB (French-American-British) classifications (Figure 3A, Supplemental Table 4). Although AML with maturation (FAB M2) was the most common (19/43, 44.2%), cases with FAB M6 (erythroid) features were also observed, as was also recently described for UBTF-TD AMLs in adults(9). Morphologic assessments also revealed that UBTF-TD cases often displayed pleomorphic blasts (Figure 3B), accompanied by background multilineage dysplasia and increased erythroid precursors. UBTF-TD AMLs showed lower white blood cell count (median = 8.4x10^9/L, IQR = 41.4x10^9/L) and bone marrow blast percentage (mean = 33%, IQR = 41.4%) when compared to other AMLs, including those with similar transcriptional profiles like AML with NUP98-rearrangements or NPM1 mutations(1, 4) (Figure 3C-D). FLT3-ITD, but not WT1 mutations, were associated with a higher WBC count and bone marrow blasts in UBTF-TD AMLs (Figure 3E). Despite the presence of dysplastic features, cytogenetic studies commonly found either a normal karyotype (58/95, 61.1%) or trisomy 8 (27/95, 28.4%), and myelodysplasia-related chromosomal changes or myelodysplasia-related mutations were overall rare, suggesting that UBTF-TD itself contributes to dysplastic features (Supplemental Table 4). Considering these overall
features, the majority of UBTF-TD AMLs (83/89, 93.3%) are best classified as “Acute myeloid leukemia with other defined genetic alterations” in the current WHO classification (25) (Supplemental Table 4).

Transcriptional features of UBTF-TD myeloid neoplasms

We and others have previously shown that AML with UBTF-TD is characterized by high HOXA and HOXB cluster gene expression, similar to NPM1-mutated or NUP98::NSD1 AML (1, 4, 8). To further define the unique expression profiles of UBTF-TD, we established an RNA-seq cohort consisting of various AML subtypes (1) (n=837), cord blood CD34+ samples from healthy donors (n=5), and UBTF-TD AML and MDS samples (n=94: 1 UBTF-TD case did not have RNA-seq data available) (Figure 4A). Consistent with previous data, UBTF-TD cases clustered with NPM1-mutated and NUP98::NSD1 AMLs. However, UBTF-TD displayed a significantly higher expression of a subset of HOXB cluster genes (e.g., HOXB8, HOXB9) compared with NUP98::NSD1 AML (Figure 4B). We also observed uniquely high expression of histone genes (e.g., HIST1H4F and HIST1H2B1) compared to NPM1-mutated AML (Figure 4C), suggesting transcriptional mechanisms unique to UBTF-TD AML. Within UBTF-TD samples, those with FLT3-ITD and WT1 mutations showed unique distribution on the UMAP cluster (Figure 4D), and each mutation group demonstrated differential gene expression against UBTF-TD samples without either mutation (Figure 4E). Co-occurrence of WT1 and FLT3-ITD was associated with stemness-related genes (e.g., CD34 and DNTT, Figure 4E-F), and Gene Set Enrichment Analysis (GSEA) confirmed enrichment of stemness or cell cycle-related gene expression in WT1+FLT3-ITD+ UBTF-TD samples.
These results show the unique expression profile of UBTF-TD AML and the specific influence of additional cooperating mutations, which can likely influence patterns of clonal evolution.

**Exon 9 tandem duplications in UBTF**

Given the recurrent UBTF exon 13 alterations duplicating specific hydrophobic amino acid sequences, we hypothesized that UBTF alterations outside exon 13 resulting in similar amino acid sequences could be found in cases without defining alterations but with a similar expression signature. By close inspection of the UBTF gene using RNA-sequencing data, we found two pediatric AML cases without exon 13 UBTF-TD or other driver alterations that instead have in-frame tandem duplications (lengths of 78 and 153bp) in exon 9 of UBTF (TD-exon9), encoding short hydrophobic amino acid sequences (**Figure 5A-B**). These cases express HOXA/B cluster genes comparably to exon 13 UBTF-TD (**Supplemental Figure 1**), and one had a WT1 mutation (**Supplemental Table 5**). To test whether these exon 9 duplication events could lead to leukemic transformation, we expressed both exon 9 duplications in cbCD34+ cells using lentiviral vectors and assessed their impact on cell proliferation, clonogenic potential, and cellular morphology in comparison with control conditions and exon 13 UBTF-TD (**Figure 5C-D**). Colony forming unit (CFU) assay revealed that expression of both UBTF-TD-exon9 increased total colony number (**Figure 5E**). After the second round of replating, cells with UBTF-TD-exon9 showed an immature morphology along with erythroid features, similar to exon 13 UBTF-TD expressing cells (**Figure 5F**). Furthermore, cells expressing UBTF-TD-exon9 as well as UBTF-TD-exon13 showed a
proliferative advantage compared to UBTF-WT and vector controls (Figure 5G).

Collectively, these data highlight a tandem duplication in UBTF exon 9 as a defining alteration functionally equivalent to exon 13 tandem duplications.

Discussion:

In this study, we extended our cohort of pediatric myeloid malignancies with exon 13 UBTF-TD, which now includes 95 pediatric cases. Similar to studies in adults (9), pediatric myeloid tumors with UBTF-TD are associated with lower bone marrow blast infiltration and lower white blood cell count, suggesting a similar clinical presentation. In this pediatric cohort, we observed that UBTF-TD is associated with an M2 morphology subtype (44.2%) according to FAB classification (27). These morphological features align with findings in adult cases, which showed a high prevalence of FAB M6 and M2 cases (9). Furthermore, the presence of dysplastic features and the observation that UBTF-TD occurs in cases of pediatric MDS suggest that MDS and AML could be part of a continuum driven by UBTF-TD. Progression to AML may require the acquisition of cooperating mutations such as FLT3-ITD, supported by the finding that none of the MDS cases in this cohort harbor a FLT3-ITD alteration.

To evaluate the impact of these cooperating mutations on cellular status, we analyzed RNA-seq data of UBTF-TD cases with or without mutations, showing that the co-occurrence of FLT3-ITD and WT1 is strongly associated with stem cell features and represented by CD34 expression or quiescent states. These findings were further supported by single cell studies. Given that WT1 mutations are often subclonal
alterations that expand at relapse and that the co-occurrence of these mutations is associated with particularly dismal outcomes (4), acquiring these stem-like features can contribute to resistance to conventional chemotherapy. Furthermore, a recent study showed that UBTF-TD localizes to HOXA/B genomic regions and that Menin inhibition is sufficient to promote terminal differentiation (28). How these other mutations co-operate with UBTF-TD to maintain stem cell features requires further evaluation.

Given that exon 13 UBTF-TD has been underappreciated in standard computational pipelines, we investigated other possible UBTF alterations in pediatric AML cases without a defined driver event and demonstrated that in-frame tandem duplications in exon 9 of UBTF are possible driver alterations. Although rare within cases with UBTF alterations (2/97 UBTF-TD cases, 2.1%), cases with tandem duplications in exon 9 show similar transcriptional profiles to exon 13 UBTF-TD AML. We further show that exon 9 alterations can induce leukemic changes, including hematopoietic cell growth and increased clonogenicity in cbCD34+ cells similar to exon 13 alterations. At the amino acid level, exon 9 tandem duplications contain amino acid sequences (LKDKFDGLTI) that share hydrophobic α-helix structure with recurrently duplicated sequences in exon 13 tandem duplications (LTRLLARM), suggesting a shared mechanism. Importantly, PCR-based screening can underestimate PTD or these exon 9 alterations since they are outside the covered regions(9), and we propose that enhanced sequencing-based strategies are needed to accurately diagnose this entity. The findings presented here will help build on our understanding of UBTF-TD myeloid
neoplasms and further support its recognition as a distinct entity in future classification systems.

Acknowledgements:
The work was funded by the American Lebanese and Syrian Associated Charities of St. Jude Children's Research Hospital and funds from the US NIH, including F32 HL154636 (JMB), U54 CA243124 and R01 CA276079 (JMK). The content, however, does not necessarily represent the official views of the NIH and is solely the responsibility of the authors. The studies were also funded by the Jane Coffin Childs Fund (JMB). JMK holds a Career Award for Medical Scientists from the Burroughs Welcome Fund. Support was also provided by Shared Resources provided through the St. Jude Comprehensive Cancer Center (P30-CA21765), Flow Cytometry and Cell Sorting, Comparative Pathology Core, and Genome Sequencing (Hartwell Center).

Author Contributions:
Competing Interests: C.Y., B.O., and M.A. are employed by Mission Bio, Inc. No other authors have conflicts to declare.

Data Availability Statement:
Samples from patients with MDS or AML from St. Jude Children’s Research Hospital tissue resource core facility were obtained with written informed consent using a protocol approved by the St. Jude Children’s Research Hospital institutional review board (IRB). Studies were conducted in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects. The expression data newly generated in this study (RNA-Seq: n=3) and scDNA + protein sequencing (n=3) have been deposited in the European Genome-Phenome Archive (EGA) which is hosted by the European Bioinformatics Institute (EBI), under accession EGAS00001005760. The remaining RNA-Seq data are available via EGA, St. Jude Cloud or TARGET as defined in Supplemental Table 6. Information about TARGET can be found at http://ocg.cancer.gov/programs/target. Other data generated in this study are available in the Supplemental tables or upon request to the corresponding author.

Citations:


Figure Legends:

Figure 1. Characterization of Tandem Duplications in Exon 13 of UBTF. A. Genomic representation of duplicated regions (grey) from 95 cases with UBTF exon 13 duplications. A common duplicated region is outlined in red with the alignment of the resulting amino acid sequence. B. Size assessment of exon 13 resulting from the duplicated regions and associated insertion/deletions. For partial tandem duplications (n=13) extending beyond exon 13, sizes of duplicated exon 13 with insertions or deletions are included. C. Genomic landscape of UBTF-TD cases. For each case, variant allele frequency (VAF), diagnosis, karyotype, and sex are shown. D. Distribution of cytogenetic changes among UBTF-TD cases. E. Ribbon plot depicting association of cytogenetics with mutations common in UBTF-TD myeloid neoplasms. Genes coding for proteins involved in RAS/MAPK pathway are grouped together (NF1, PTPN11, NRAS, KRAS, RIT1, CBL). All other mutations in FLT3 not classified as ITD were grouped into FLT3-other. F. Ribbon plot depicting the association of co-occurring mutations in the UBTF-TD cohort. Genes with only one occurrence were excluded.

Figure 2. Clonal Dynamics of UBTF-TD Leukemias. A. Single-cell DNA sequencing coupled with surface marker expression of UBTF-TD case at diagnosis. Heatmap depicting the presence of mutant allele (bottom) and relative protein abundance (top). B. Schematic of clonal structure in UBTF-TD case from A. Percentages are calculated as a proportion of total cells with a somatic mutation. C. Single-cell DNA sequencing of a UBTF-TD case with diagnosis (left) and relapse (right) paired samples. Heatmap depicts the presence of a mutant allele and protein
expression. D. Schematic of clonal dynamics in diagnosis/relapse case from C. Percentages are calculated as a proportion of total cells with a somatic mutation.

Figure 3. Morphological and Biological Assessment of UBTF-TD. A. Available FAB (French-American-British) classification of UBTF-TD AMLs (n=43). B. Representative Wright-Giemsa Staining of bone marrow (BM) aspirates and peripheral blood (PB) smears from 4 unique UBTF-TD cases. Case ID, FAB/WHO classification, along with FLT3 and WT1 mutation status, are labeled above. **UBTF-TD-3-Childhood MDS with increased blasts**: increased erythroid cells with dysplastic morphologic features (top), dysplastic myeloid cells with salmon-colored granules, and dysplastic small megakaryocytes (bottom). **UBTF-TD-78-AML with other defined genetic alterations (Acute myeloid leukemia with maturation)**: characteristic blasts and myeloid precursor cells with salmon-colored granules (top) and blasts with small Auer rods (bottom). **UBTF-TD-91-AML with other defined genetic alterations (Acute myelomonocytic leukemia)**: blasts with both myeloid and monocytic/monoblastic morphologic features. PB in this patient is one of the few cases in our cohort showing hyperleukocytosis with many circulating blasts (bottom). **UBTF-TD-90-AML with other defined genetic alterations (Acute myelomonocytic leukemia)**: dysplastic megakaryocytes, increased erythroid cells with dysplastic morphologic features, and blasts, many with monocytic/monoblastic morphologic features. C. White blood cell counts (WBC) for a pediatric AML cohort stratified by oncogenic driver subtypes. D. Bone marrow blast percentage for a pediatric AML cohort stratified by oncogenic driver subtypes. E. WBC count and BM blast percentage among UBTF-TD cases with different WT1 and FLT3 mutation status.

Figure 4. Transcriptional characterization of UBTF-TD leukemias. A. UMAP (Uniform Manifold Approximation and Projection) of expression profiles across a cohort of UBTF-TD...
(n=94) and pediatric AML (n=839), adapted from a previous study(4). Each dot is colored by subtype-defining alterations. The black box outlines a cluster of cases with HOXA/HOXB dysregulation, which includes all UBTF-TD cases. B. Differentially expressed genes between UBTF-TD AML and NUP98::NSD1 pediatric AML. Representative genes are annotated. C. Differentially expressed genes between UBTF-TD AML and NPM1-mutated pediatric AML. D. Distribution of UBTF-TD cases within the cluster with HOXA/B dysregulation. Each data is colored by the mutational status of UBTF-TD, FLT3-ITD, or WT1. MDS cases are depicted with triangles, and AML cases are with circles. E-top. Schematic depicting the transcriptional comparison of UBTF-TD cases by mutational status. -bottom. Venn diagram showing overlap of differentially expressed genes in FLT3-ITD only cases and FLT3-ITD+/WT1+ cases compared with cases without these mutations. F. Expression CD34 and DNTT with respect to FLT3 and WT1 mutational status. G. GSEA of UBTF-TD cases based on mutational status.

Figure 5. Exon 9 UBTF Tandem Duplications in Pediatric AML. A. Identification of UBTF-TD cases with tandem duplications in exon 9 of UBTF. UBTF-TD-exon9 on the UMAP plot of the Pediatric AML cohort (red circles), adapted from a previous study(4). B. Schematic of UBTF protein, highlighting amino acid sequences encoded in exon 9 of UBTF-WT, UBTF-TD78-exon9, UBTF-TD153-exon9. Duplications resulting in short hydrophobic sequences are labeled in red. Hydrophobic residues are underlined. C. Experimental design to evaluate the transforming potential of UBTF-TD-exon9 mutants D. Immunoblot of lysates from cbCD34+ transduced with UBTF-TD-exon9 vectors and corresponding controls. Antibodies against HA-tag, UBTF, and β-actin were used. E. Colony forming unit assay. 2-way ANOVA with two-sided Dunnett’s test was applied with UBTF-WT as control F. Cytospins isolated from CFU assay at round 2 of replating (Wright-Giemsa Staining, 400X magnification). G. In vitro growth curves of cbCD34+ cells expressing controls or UBTF-TD-e9 mutants. 2-way ANOVA with Dunnett’s test was applied with UBTF-WT as control.
Figure 2

A

UBTF-TD-67 - Diagnosis
Total Cells: 674
Normalized Counts

UBTF-TD
Not Detected Mutant
CD34
CD117
CD123
CD19
CD3
NRAS p.G12D
FLT3 p.V892D
WT1 p.V334fs
UBTF-TD

B

UBTF-TD
21.5%
cells: 124

UBTF-TD
WT1 p.V334fs
41.8%
cells: 242

UBTF-TD
WT1 p.V334fs
23.7%
cells: 137

C

UBTF-TD-91 - Diagnosis
Total Cells: 1122
Normalized Counts

UBTF-TD
Not Detected Mutant
CD34
CD117
CD123
CD19
CD3
WT1 p.R375fs
FLT3-ITD
UBTF-TD

D

UBTF-TD
FLT3-ITD
WT1 p.R375fs
1.9%
cells: 20

UBTF-TD
98.1%
cells: 1051

UBTF-TD
FLT3-ITD
WT1 p.R335fs
19.3%
cells: 125

UBTF-TD
FLT3-ITD
WT1 p.R335fs
NBEAL2 p.T1454fs
19.3%
cells: 524

Therapy
Figure 3

A. Pie chart showing the distribution of FAB types with a total of 43 samples. The distribution is as follows:
- M0: 13.9%
- M1: 4.7%
- M2: 16.3%
- M4: 7.0%
- M5: 44.2%

B. Images showing bone marrow samples labeled as follows:
- UBTF-TD-3: Bone Marrow x1000
- UBTF-TD-78: Bone Marrow x1000
- UBTF-TD-91: Bone Marrow x600
- UBTF-TD-90: Bone Marrow x1000

C. Bar charts showing BM Blasts (% of BM cellularity) for different genes:
- RUNX1/RUNX1T1
- CBFB-MYH11
- KMT2A
- NUP98
- KMT2A

D. Box plots showing WBC x10^3/μL for different genes:
- RUNX1/RUNX1T1
- CBFB-MYH11
- KMT2A
- NUP98
- CBFB-MYH11

E. Violin plots showing BM Blasts (% of BM cellularity) for different conditions:
- UBTF-TD
- UBTF-TD/WT/FL3/TTD
- UBTF-TD/WT/FL3/TTD